

Care Index:

Community Oncology at a Pivotal Moment


85% of Americans living with cancer are treated where cancer meets care, in community practices.ⁱ These community oncologists are embracing new tools, treatments and models of care at a rapid pace. But confidence alone does not change clinical practice. To turn readiness into real-world impact, community practices need education, infrastructure, technology and support to help innovation reach more patients, faster.

Johnson & Johnson's 2026 Oncology Care Index surveyed 109 community oncologists (oncologists, n=99; hematologists, n=10) and 100 practice administrators (oncology, n=92; hematology, n=8) in the U.S. to better understand where community oncology stands today, and where the greatest opportunities – including artificial intelligence (AI) adoption – exist to advance cancer care in community settings. Healthcare professionals and physicians who qualified for and successfully completed the survey were compensated for their participation.

Building on findings from the [2025 Oncology Care Index](#) that surveyed a broad spectrum of oncology professionals nationwide on the challenges of keeping pace with rapid treatment advances, this year's Index goes deeper into learning about the challenges and opportunities among community oncologists and their care teams, where innovations and daily patient care most often intersect.


Confidence meets a complicated reality

Community oncologists are bringing many of the innovations reshaping cancer care into real-world practice, but a critical paradox remains between confidence and implementation.



AI is just the beginning: where innovation meets its next test

Community oncology is at a pivotal moment. AI presents unprecedented rapid advances in understanding of cancer biology and optimization of patient care.ⁱⁱⁱ

 Dedicated support across three key areas can turn readiness into everyday impact.

Moving AI adoption from promise to practice

Community oncology's AI boom faces a practical test: turning early use into everyday impact


AI is increasing in community oncology, but the next opportunity is moving from familiarity and early adoption to sustained, trusted use in everyday workflows.



Potential to make clinical trial access easier closer to home

Cancer clinical research has a participation problem. Community oncology may hold the answer.^v


Community-based trials may be a pathway to broader access to clinical trials. Reimagining trials around real-world community care may help make research easier to offer and join where patients are treated.



Advancing delivery of care regardless of zip code

Emerging immunotherapies are moving into community cancer care, but confidence gaps remain

Community oncology is well-positioned to bring the next wave of cancer innovation closer to patients, but the next opportunity is helping practices move from readiness to deeper confidence and capacity.



Closing the gap starts here:

Three opportunity areas, one shared goal – bringing innovation to where cancer meets care, every day, in community oncology practices across the country.



References:

i. Association of Cancer Care Centers. ACCC Community Oncology Research Institute. Available at: <https://www.accc-cancer.org/education-and-resources/research/accc-community-oncology-research-institute>.

ii. Johnson & Johnson Oncology & The Harris Poll. About the Survey: This survey was conducted online within the United States by The Harris Poll on behalf of Johnson & Johnson Oncology, from May 21-July 6, 2026 among 109 community oncologists and 100 practice managers or administrators whose practices specialize in hematology/oncology, treating both hematologic and solid tumor cancers in community settings across the U.S.

iii. National Cancer Institute. (2024, May 30). AI and cancer. <https://www.cancer.gov/research/infrastructure/artificial-intelligence>

iv. Johnson & Johnson Oncology & The Harris Poll. About the Survey: This survey was conducted online within the United States by The Harris Poll on behalf of Johnson & Johnson Oncology, from November 21-December 13, 2024 among 500 adults age 18+ who are duly licensed and either hematologists/oncologists, urologists, APPs in hematology/oncology, or APPs in urology (MDs in Oncology [n=221], MDs in Urology [n=160], Advanced Practice Providers [APPs] in Oncology [n=102], and APPs in Urology [n=17]). Oncologists and APP oncologists treat at least 1 patient with blood and 1 patient with solid-state tumor cancer, while urologists and APP urologists treat at least 1 patient with solid-state tumor cancer.

v. National Community Oncology Dispensing Association. (2025, October). The challenge of patient enrollment in clinical trials. NCODA. <https://ncoda.org/news/the-challenge-of-patient-enrollment-in-clinical-trials/>